SCHEMBL4906495

SCHEMBL4906495

CCCS(=O)(=O)Oc1ccc(-c2c(CN3C(=O)c4ccccc4C3=O)c(C(=O)NN3CCCCC3)nn2-c2ccc(Cl)cc2Cl)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 10/20 0.58
CNR2 P34972 5/20 0.58
ABCC4 O15439 1/20 0.53
MLNR O43193 1/20 0.53
ABCB11 O95342 1/20 0.53
CHRM2 P08172 1/20 0.53
ADORA3 P0DMS8 1/20 0.53
CYP2C9 P11712 1/20 0.53
ADRA2B P18089 1/20 0.53
ADRA2C P18825 1/20 0.53
DRD1 P21728 1/20 0.53
TBXA2R P21731 1/20 0.53
SLC6A2 P23975 1/20 0.53
HRH2 P25021 1/20 0.53
HTR2A P28223 1/20 0.53
AGTR1 P30556 1/20 0.53
CCKAR P32238 1/20 0.53
CCKBR P32239 1/20 0.53
MC4R P32245 1/20 0.53
ABCC1 P33527 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4910495 0.88 CNR1 (0.65) CNR1CNR2ABCC4MLNRABCB11
SCHEMBL4910871 0.88 CNR1 (0.65) CNR1CNR2ABCC4MLNRABCB11
SCHEMBL4903862 0.88 CNR1 (0.66) CNR1CNR2ABCC4MLNRABCB11
SCHEMBL3813720 0.85 CNR1 (0.74) CNR1CNR2ABCC4MLNRABCB11
SCHEMBL3815422 0.84 CNR1 (0.64) CNR1CNR2ABCC4MLNRABCB11
Hydrochloric Acid SCHEMBL4604024 0.84 CNR1 (0.74) CNR1CNR2ABCC4MLNRABCB11
SCHEMBL4906553 0.84 CNR1 (0.51) CNR1CNR2ABCC4MLNRABCB11
SCHEMBL3814159 0.81 CNR1 (0.72) CNR1CNR2ABCC4MLNRABCB11
SCHEMBL4908643 0.79 CNR1 (0.62) CNR1CNR2ABCC4MLNRABCB11
SCHEMBL3814893 0.78 CNR2 (0.75) CNR1CNR2ABCC4MLNRABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080146614-A1 Therapeutic Agents ASTRAZENECA AB (SE) 2008-06-19 US disclosed
EP-1831177-A1 THERAPEUTIC AGENTS AstraZeneca AB (SE) 2007-09-12 EP disclosed
WO-2006067443-A1 THERAPEUTIC AGENTS ASTRAZENECA AB (SE) 2006-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146614-A1 Therapeutic Agents BDNF, NLN, GRIN2C CNR1 597/4885CNR2 480/4885ABCC4 471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.